What is the ICD-10 code for fibrocystic breast changes?

The ICD-10 code for fibrocystic breast changes without epithelial proliferation is N60.19. If laterality is specified, use N60.11 for the right breast and N60.12 for the left breast.

How do you code fibrocystic breast changes with epithelial proliferation?

For fibrocystic breast changes with epithelial proliferation, use the ICD-10 code N60.3-. This requires biopsy confirmation of epithelial proliferation.

ICD-10 Coding for Fibrocystic Breast Changes(N60.19, N60.0, N60.11)

Save

Learn about the ICD-10 coding for fibrocystic breast changes, including documentation requirements and common coding pitfalls. Ensure accurate billing and compliance.

Also known as:

Fibrocystic DiseaseDiffuse Cystic MastopathyBenign Breast Disease

Related ICD-10 Code Ranges

Complete code families applicable to Fibrocystic Breast Changes

N00-N99Primary Range

Diseases of the genitourinary system

→

Code Comparison: When to Use Each Code

Compare key differences between these codes to ensure accurate selection

Code	Description	When to Use	Key Documentation
N60.19	Diffuse Cystic Mastopathy, Unspecified	Use when fibrocystic changes are present without epithelial proliferation.	Ultrasound showing multiple cysts Mammogram indicating dense breast tissue Absence of atypia on biopsy
N60.11	Diffuse Cystic Mastopathy, Right Breast	Use when fibrocystic changes are confirmed in the right breast.	Ultrasound confirming right breast cysts Mammogram indicating right breast density
N60.12	Diffuse Cystic Mastopathy, Left Breast	Use when fibrocystic changes are confirmed in the left breast.	Ultrasound confirming left breast cysts Mammogram indicating left breast density

Primary ICD-10-CM Codes

Diffuse cystic mastopathy of unspecified breast

N60.19Billable

Differential Codes

Alternative codes to consider when ruling out similar conditions

Fibrocystic Changes with Epithelial ProliferationN60.3

Documentation & Coding Risks

Avoid these common issues when documenting Fibrocystic Breast Changes.

Omitting laterality in documentation

Impact

Clinical: May lead to misinterpretation of clinical findings., Regulatory: Non-compliance with coding standards., Financial: Potential for claim denials.

Mitigation

Use templates that prompt for laterality, Review documentation for completeness before submission

Unspecified laterality

Impact

Reimbursement: May lead to claim denials or reduced reimbursement., Compliance: Non-compliance with ICD-10 specificity requirements., Data Quality: Decreases accuracy of clinical data.

Mitigation

Always specify laterality when coding fibrocystic changes.

Confusion with benign neoplasms

Impact

Reimbursement: Incorrect coding may affect DRG assignment., Compliance: Potential for audit issues., Data Quality: Impacts clinical data integrity.

Mitigation

Differentiate fibrocystic changes from benign neoplasms through imaging and biopsy.

Laterality Documentation

Impact

Failure to document laterality can lead to audit issues.

Mitigation

Implement mandatory fields for laterality in EHR templates.

Frequently Asked Questions

Documentation requirements, coding pitfalls and FAQs for conditions coded with N60.19.

Primary Code

N60.19

Diffuse cystic mastopathy of unspecified breast

Quick Navigation

ICD-10 codes8

Coding risks4

FAQs2

ICD-10 Coding for Fibrocystic Breast Changes(N60.19, N60.0, N60.11)

Documentation & Coding Risks

Frequently Asked Questions

What is the ICD-10 code for fibrocystic breast changes?

How do you code fibrocystic breast changes with epithelial proliferation?

Related condition guides